Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 1.55 +0.12 (+8.01%) (As of 12:32 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines HEMO vs. ORPH, REDX, ETX, TRX, POLB, SBTX, COS, C4XD, DDDD, and SARShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Poolbeg Pharma (POLB), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Sareum (SAR). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. Open Orphan Redx Pharma e-therapeutics Tissue Regenix Group Poolbeg Pharma SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Sareum Open Orphan (LON:ORPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Is ORPH or HEMO more profitable? Open Orphan's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Open OrphanN/A N/A N/A Hemogenyx Pharmaceuticals N/A -155.97%-37.79% Do institutionals and insiders have more ownership in ORPH or HEMO? 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer ORPH or HEMO? Hemogenyx Pharmaceuticals received 55 more outperform votes than Open Orphan when rated by MarketBeat users. Likewise, 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote while only 0.00% of users gave Open Orphan an outperform vote. CompanyUnderperformOutperformOpen OrphanOutperform VotesNo VotesUnderperform Votes2100.00% Hemogenyx PharmaceuticalsOutperform Votes5557.89% Underperform Votes4042.11% Which has preferable earnings & valuation, ORPH or HEMO? Open Orphan has higher revenue and earnings than Hemogenyx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpen Orphan£34.71M1.93N/AN/AN/AHemogenyx PharmaceuticalsN/AN/A-£5.18M-£0.01-155.00 Does the media favor ORPH or HEMO? In the previous week, Open Orphan had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Open Orphan and 0 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 beat Open Orphan's score of -0.02 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Open Orphan Neutral Hemogenyx Pharmaceuticals Neutral SummaryOpen Orphan and Hemogenyx Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£20.77M£138.75M£5.10B£1.39BDividend YieldN/A3.50%5.04%11.86%P/E Ratio-155.00331.5795.621,573.12Price / SalesN/A15,233.371,217.19212,245.03Price / Cash2.0511.7539.5933.11Price / BookN/A7.206.942.79Net Income-£5.18M-£18.56M£118.89M£154.04M7 Day Performance42.59%0.17%-1.33%-0.59%1 Month Performance11.99%8.18%-3.17%7.21%1 Year Performance-37.25%25.53%32.49%94.65% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 1.55+8.0%N/A-42.6%£20.77MN/A-155.0014Gap DownORPHOpen OrphanN/AGBX 10+5.3%N/A+0.0%£67.09M£34.71M-25.30179REDXRedx PharmaN/AGBX 15+31.6%N/A-40.0%£58.35M£4.20M-150.00101News CoverageGap UpHigh Trading VolumeETXe-therapeuticsN/AGBX 9-6.7%N/A-13.9%£52.59M£295,000.00-450.0035High Trading VolumeTRXTissue Regenix GroupN/AGBX 56-5.1%N/A+4.7%£39.89M£31.80M-5,926.70120POLBPoolbeg PharmaN/AGBX 7.60flatN/A-17.4%£38MN/A-770.0012News CoveragePositive NewsSBTXSkinBioTherapeuticsN/AGBX 16-1.5%N/A-21.4%£36.17M£21,949.00-800.0011COSCollagen Solutions plc (COS.L)N/AGBX 6.63flatN/A+0.0%£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AGBX 12+27.3%N/A-4.2%£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AGBX 16.66flatN/A+0.0%£30.05M£718,000.00-1.08106SARSareumN/AGBX 26.34+1.3%N/A-56.9%£28.43M£47,204.00-440.003,211Gap Up Related Companies and Tools Related Companies Open Orphan Alternatives Redx Pharma Alternatives e-therapeutics Alternatives Tissue Regenix Group Alternatives Poolbeg Pharma Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Sareum Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:HEMO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
